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Abstract
The adhesion of osteoblasts to bone extracellular matrix, of which type-I collagen constitutes >85%, can modulate diverse
aspects of their physiology such as growth, differentiation and mineralisation. In this study we examined the adhesion of
UMR106 rat osteoblast-like cells either to a control (Col) or advanced-glycation-endproduct-modified (AGEs-Col) type I
collagen matrix. We investigated the possible role of different integrin receptors in osteoblastic adhesion, by co-incubating
these cells either with b-peptide (conserved sequence 113–125 of the b subunit of integrins) or with two other peptides,
RGD (Arg-Gly-Asp) and DGEA (Asp-Gly-Glu-Ala), which are recognition sequences for the a-subunits of a1,5b1 and
a2b1 integrins. Collagen glycation inhibited the adhesion of UMR106 osteoblasts to the matrix (40% reduction versus Col,
P < 0.001). b-Peptide showed a dose- and glycation-dependent inhibitory effect on adhesion, and at a concentration of
100 mM decreased the attachment of UMR106 cells to both matrices (42% to Col, P < 0.001; and 25% to AGEs-Col,
P < 0.01). The synthetic peptides RGD (1 mM) and DGEA (5 mM) inhibited the attachment of UMR106 cells to Col (30 and
20%, P < 0.01 and P < 0.001, respectively), but not to AGEs-Col. b-Peptide induced an increase in UMR106 cell clumping
and a decrease in cellular spreading, while DGEA increased spreading with cellular extensions in multiple directions. These
results indicate that both a and b integrin subunits participate in osteoblastic attachment to type-I collagen, probably through
the a1,5b1 and a2b1 integrins. AGEs-modification of type-I collagen impairs the integrin-mediated adhesion of osteoblastic
cells to the matrix, and could thus contribute to the pathogenesis of diabetic osteopenia.
© 2003 Elsevier Ltd. All rights reserved.
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1. Introduction
The processes of bone formation and bone turnover
depend on an adequate recruitment, growth and de-
velopment of osteoblastic cells (Schenk, Felix, &
Hofstetter, 1993). In turn, the attachment and spread-
ing of these cells to an extracellular matrix or ECM
(first steps in osteoblastic progression), are dependent
on the interaction between various cellular adhesion
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molecules and their consensus sequences present in
ECM proteins (Ducy, Schinke, & Karsenty, 2000).
Pre-eminent among these adhesion molecules are the
integrin receptors or integrins.
To date, multiple integrin receptors have been de-
scribed in osteoblasts. Integrins, by interaction of their
a and b subunits with certain consensus sequences
present in ECM proteins, can aid in osteoblastic
adhesion and spreading, as well as in intracellular
signalling. The consensus sequences for binding of a
subunits have been well characterised. Thus the a sub-
unit of a2b1, considered to be the main osteoblastic
receptor for type-I collagen (which in turn constitutes
>85% of bone ECM), recognises the tetrapeptide
sequence DGEA (Asp-Gly-Glu-Ala) present in this
collagenous molecule (Takeuchi, Nakayama, &
Matsumoto, 1996). On the other hand, the a sub-
units of integrins a1b1 and a5b1 principally recog-
nise the tripeptide sequence RGD (Arg-Gly-Asp),
which is present in several ECM proteins such as
type-I collagen, fibronectin, vitronectin and osteo-
pontin (Ruoslahti, 1991). However, the consensus
sequences for binding of b subunits to ECM have
proved to be more difficult to define. Recently, an
ingenious approach to bypass this particular problem
Fig. 1. Schematic structure of an integrin receptor and the b-peptide.
was developed by Dr. Uemura and associates (Yabe,
Nemoto, & Uemura, 1997; Uemura et al., 1997; Liu,
Nemoto, Feng, & Uemera, 1997; Sun et al., 2000;
Uemura, Nemoto, & Liu, 2000). Since all integrin
b subunits are almost identical with respect to their
amino acid sequences, these investigators designed
and synthesised the polypeptide Asp-Leu-Tyr-Tyr-
Leu-Met-Asp-Leu-Ser-Tyr-Ser-Met-Lys (referred to
as the b-peptide), which corresponds to the conserved
amino acid sequence 113–125 of the b subunits of
integrins (Fig. 1). The b-peptide was found to inhibit
the binding of cellular integrins to ECM proteins, pre-
sumably due to competition for the same consensus
sequence(s). In addition, biotinylated b-peptide was
able to bind efficiently to immobilised fibronectin, fib-
rinogen, vitronectin or type-I collagen, with varying
degrees of affinity (Liu et al., 1997).
In conditions associated with chronic hypergly-
caemia, hyperlipidaemia, and/or oxidative stress (such
as ageing, Alzheimer’s disease, uraemia and Dia-
betes mellitus), there is an increase in the steady-state
levels of reactive dicarbonylic compounds or “car-
bonyl stress”, leading to an accumulation of advanced
glycation-end products (AGEs) on long-lived proteins
(Vlassara, Bucala, & Striker, 1994; Baynes & Thorpe,
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1999). In particular, this accumulation of AGEs is
postulated to be involved in the pathogenesis of di-
abetic chronic complications including osteopenia
(Vlassara, 1997; McCarthy, 2000), which has recently
been attributed to a decrease in osteoblast recruitment
and bone-forming capacity (Krakauer et al., 1995).
Our group and other investigators have shown
that AGEs-modified proteins can exert direct effects
on osteoblast-like cells in culture (Miyata, Kawai,
Taketomi, & Sprague, 1996; Katayama, Akatsu,
Yamamoto, Kugai, & Nagata, 1996; Takagi et al.,
1997; Paul & Bailey, 1999; McCarthy, Etcheverry,
Bruzzone, & Cortizo, 1997; McCarthy, Etcheverry,
& Cortizo, 1999; McCarthy, Etcheverry, Bruzzone et
al., 2001; McCarthy, Etcheverry, Cortizo et al., 2001;
Cortizo et al., 2003). In particular, we have found that
AGEs can depress osteoblastic function at several
stages of their development. Thus, AGEs-modification
decreases the attachment of osteoblastic UMR106
cells to a type-I collagen matrix; and long-term expo-
sure to AGEs depresses: (a) the proliferation and dif-
ferentiation of UMR106 and MC3T3E1 osteoblasts,
and (b) the formation of nodules of mineralisation by
MC3T3E1 cells. These effects on osteoblasts could be
occurring as a consequence of an interaction between
AGEs structures and their specific receptors, which
we have recently described in osteoblasts (McCarthy
et al., 1999; Cortizo et al., 2003). However, they
could also be a consequence of an impaired interac-
tion between other osteoblastic receptors and their
AGEs-modified physiological extracellular ligands.
The object of this study was to investigate whether
formation of AGEs on type-I collagen impairs its
interaction with UMR106 osteoblast integrin recep-
tors, thereby providing a possible explanation for the
decreased attachment of osteoblastic UMR106 cells
to an AGEs-modified type-I collagen matrix which
we have previously described (McCarthy, Etcheverry,
Bruzzone et al., 2001).
2. Materials and methods
2.1. Materials
Ribose, rat tail acid-soluble type I collagen, RGD
peptide and DGEA peptide were purchased from
Sigma (St. Louis, MO, USA). The b-peptide was
synthesised by the Peptide Institute in Osaka, Japan;
the purity of this synthetic product was calculated
to be 95.1% by HPLC analysis (Liu et al., 1997).
Dulbecco’s modified Eagle’s medium (DMEM),
trypsine-EDTA and fetal bovine serum (FBS) were
obtained from Gibco (Life Technology, Argentina).
Tissue culture disposable material was from Nunc.
All other chemicals and reagents were obtained from
commercial sources and were of analytical grade.
2.2. Preparation of control and AGEs-modified
type-I collagen matrices
Type I collagen was solubilized in sterile 0.02 N
acetic acid (2.5 mg/ml) (pH 3.0), poured into plas-
tic dishes (50 mg/cm2) and incubated overnight at
37 ◦C. Collagen formed a thin film during incubation
(Katayama et al., 1996). The film was washed with
phosphate-buffered saline (PBS) and further incubated
in PBS with or without 100 mM ribose at 37 ◦C for
3 weeks in sterile conditions (McCarthy, Etcheverry,
Bruzzone et al., 2001). Finally, the plates were washed
thoroughly with DMEM and the cells were plated for
different experiments. AGEs-formation on collagen
was monitored by measuring AGEs-specific fluores-
cence emission (356 nm excitation wavelength and
440 nm emission wavelength), as we have previously
described (McCarthy, Etcheverry, Bruzzone et al.,
2001). After incubating 3 weeks with ribose, colla-
gen contained more AGEs-associated fluorescence
than control collagen incubated with PBS alone (30
versus 7.5 relative fluorescence units/mg protein, for
AGEs-modified and control collagen, respectively).
Other authors have demonstrated that prolonged in
vitro incubation of collagen with ribose leads to the
formation of AGEs, particularly arginine-derived imi-
dazolones (Paul, Avery, Slatter, Sims, & Bailey, 1998).
2.3. Measurement of free amino and guanidinium
groups on collagen matrices
The content of potentially reactive free amino gro-
ups (mainly belonging to lysine residues) on control
and AGEs-modified type-I collagen was estimated
with tri-nitro-benzene-sulphonic acid (Lavy, Brook,
Dankner, Amotz, & Aviram, 1991). The content
of free guanidinium groups (corresponding to unchan-
ged arginine residues) on control and AGEs-modified
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type-I collagen was estimated by the thymol/hypobro-
mite method (Sastry & Tummuru, 1984).
2.4. Cell culture
UMR106 rat osteosarcoma-derived cells were
grown in 75 cm2 plastic flasks at 37 ◦C in a humidified
5% CO2 atmosphere in DMEM supplemented with
10% FBS, 100 U/ml penicillin and 100 mg/l strep-
tomycin. This cell line has been shown to conserve
certain characteristics of differentiated osteoblastic
phenotype (Partridge, Alcorn, Michelangeli, Ryan, &
Martin, 1983). After 5–7 days, cells were sub-cultured
using trypsin/EDTA and replated on plastic, on con-
trol collagen or on glycated collagen to begin the
experiments.
2.5. Cell adhesion and spreading: effect of various
peptides
UMR106 osteoblast-like cells were plated in
DMEM-10% FBS on plastic, or on control or
AGEs-modified type-I collagen-coated 24 well plates,
at a seeding density of 2.5 × 105 cells/ml, in the pres-
ence or absence of different peptides: RGD (1 mM),
DGEA (5 mM), or b-peptide (50 or 100 mM). Cells
were allowed to adhere for 1 h at 37 ◦C. Each well
was then washed with PBS, fixed with methanol for
5 min and stained with Giemsa for 10 min. Cells ad-
hered to plastic or collagen matrices were evaluated
microscopically by counting several representative
fields per well. We have previously found that a lin-
ear regression of the adhesion assay occurs between
1 × 105 and 1 × 106 cells/ml (y = 0.826 + 0.759x,
r = 0.993) (McCarthy, Etcheverry, Bruzzone et al.,
2001). Cellular spreading was assessed by the obser-
vation of stained cells that presented more than one
corner, in several representative microscopic fields per
well.
Table 1
UMR106 osteoblasts were plated on different surfaces for 1 h at 37 ◦C, without competing peptides. Cell adhesion was evaluated
microscopically as described in Section 2
Surface Cell attachment (cells/field ± S.E.M.) Statistical significance
Plastic 69 ± 4
Control type-I collagen 86 ± 5 P < 0.02 (vs. plastic)
AGEs-modified type-I collagen 54 ± 4 P < 0.001 (vs. control type-I collagen)
2.6. Statistical analysis
At least three independent experiments were run for
each experimental condition. Results are expressed as
mean ± S.E.M. Statistical analysis of the data was
performed by Student’s t-test.
3. Results
3.1. Content of free lysine and arginine residues on
control and glycated collagen matrices
In the case of AGEs-modified type-I collagen, the
content of potentially reactive free amino groups
(mainly belonging to lysine residues) was 72% of
control (non-glycated) collagen. In addition, AGEs-
collagen also had a lower content (78%) of free
arginine residues than control collagen.
3.2. Osteoblastic attachment to different surfaces
As described in Section 2, UMR106 osteoblas-
tic cells were plated on plastic, or on control or
AGEs-modified type-I collagen-coated wells. In our
experimental conditions, control (non-glycated) type-I
collagen was found to be a better substratum than
plastic for the adhesion of UMR106 cells, increasing
osteoblast attachment by 25% (Table 1). However,
AGEs modification of the type-I collagen film re-
sulted in a matrix to which the osteoblasts adhered
less easily (40% reduction in adhesiveness versus
control collagen) (Table 1).
3.3. Effect of different peptides on osteoblast
attachment to collagen matrices
UMR106 cells were plated on control or AGEs-
modified type-I collagen-coated wells, in the presence



























Fig. 2. Adhesion of UMR106 osteoblastic cells to a control or
AGEs-modified type-I collagen matrix, in the presence or ab-
sence of 1 mM RGD, 5 mM DGEA or b-peptide (50 or 100 mM).
Differences versus control (cells plated without peptides) are:
∗∗P < 0.01; #P < 0.001.
or absence of different peptides that interfere with
integrin/ECM interaction. When the osteoblasts
were plated on non-glycated collagen matrices,
co-incubation with DGEA, RGD or b-peptide in-
hibited cellular adhesion in comparison with control
(no peptide) (Fig. 2). In the case of b-peptide, this
inhibition was dose-dependent and took place at mo-
lar concentrations 10–20 times lower than RGD, and
50–100 times lower than DGEA.
When UMR106 osteoblastic cells were plated on
AGEs-modified type-I collagen, coincubation with
RGD or DGEA had no effect on cell adhesion in
comparison with control (no peptide) (Fig. 2). On the
other hand, 100 mM b-peptide still retained an in-
hibitory effect on cell attachment, though significantly
less than with non-glycated collagen (Figure 2).
3.4. Effect of different peptides on osteoblastic
spreading
We next evaluated the possible effects on os-
teoblastic spreading of co-incubation with RGD,
DGEA or b-peptide. When co-incubated with b-
peptide, UMR106 cells plated both on glycated and
non-glycated collagen matrices showed an increase in
cell clumping, and a decrease in cellular spreading,
in comparison with controls (no peptide) (Fig. 3).
On the other hand, UMR106 osteoblasts plated on
non-glycated collagen in the presence of DGEA ex-
hibited greater spreading than the corresponding con-
trol (no peptide), with cellular extensions in multiple
directions (Fig. 4). However, this effect of DGEA
co-incubation on cellular spreading was not apparent
when the osteoblasts were plated on AGEs-modified
collagen (data not shown). Finally, RGD did not
induce changes in cellular spreading in any case.
4. Discussion
It has been established that sustained hypergly-
caemia and/or hyperlipidaemia can cause tissue
damage through several mechanisms, including the
accelerated formation of AGEs on both intracellular
and extracellular proteins, altering their bioactivity
and associative properties. In particular, the integrity
of the extracellular matrix (ECM) is essential to main-
tain the normal function of osteoblasts, the main cell
type involved in the formation of bone (Ng, Romas,
Donnan, & Findlay, 1997). The accumulation of AGEs
on bone type-I collagen has been previously described
in both diabetes and ageing (Locatto et al., 1993;
Tomasek, Meyers, Basinger, Green, & Shew, 1994;
Katayama et al., 1996). Thus, an AGEs-modified
ECM may have important consequences on the nor-
mal bone-forming activity of osteoblasts, possibly
through changes in cell–matrix interactions.
Osteoblasts are known to possess AGEs-specific
cell surface receptors (McCarthy et al., 1999; Cortizo
et al., 2003) whose affinity for AGEs moieties would
be expected to induce an increase in the attachment
of these cells to an AGEs-enriched collagen substra-
tum. However, in the light of our present and previous
(McCarthy, Etcheverry, Bruzzone et al., 2001) studies,
it is evident that UMR106 osteoblastic cells adhere less
easily to a type-I collagen matrix when it is modified
by AGEs. Thus, we hypothesised that this decreased
attachment might be the consequence of an impaired
interaction between other osteoblastic receptors (such
as integrins) and AGEs-modified type-I collagen.
To test this hypothesis we employed two kinds of
peptides, which we co-incubated with the osteoblasts
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Fig. 3. Effect of co-incubation with 100 mM b-peptide (C and D) on the morphological features of adhering UMR106 osteoblastic cells,
compared to control (no peptide, cells plated on type-I collagen) (A and B). Objective: 10× (A and C); 40× (B and D).
in adhesion experiments: (a) RGD and DGEA, which
mimic the consensus sequences of ECM proteins for
the a subunits of a1,5b1 and a2b1 integrin receptors,
respectively, and therefore interfere with cell adhe-
sion by binding to these integrins; and (b) b-peptide,
a 13-aminoacid conserved sequence of the b subunits
of integrins (Fig. 1), which can inhibit cell attachment
by binding to the corresponding consensus sequences
of ECM proteins. As expected, DGEA inhibited os-
teoblastic attachment to non-glycated type-I collagen
by about 20% (Fig. 2). Surprisingly however, RGD
also inhibited osteoblastic attachment to this control
matrix by about 30% (Fig. 2). This latter result differs
to reports by other authors (who found no effect of
RGD on osteoblastic adhesion to non-glycated type-I
collagen) (Takeuchi, Nakayama, & Matsumoto, 1996),
but is in agreement with the presence of RGD in type-I
collagen. Certain experimental conditions could ex-
pose this RGD sequence for interaction with a1,5b1
integrins present on osteoblasts, while different condi-
tions (such as employed by other authors) may change
type-I collagen conformation in a way which would
impede interaction due to steric hindrance. We next
used RGD, DGEA or b-peptide to try to block the ad-
hesion of UMR106 osteoblasts to an AGEs-modified
type-I collagen matrix. As a result, we found that while
b-peptide still retained roughly about half of its in-
hibitory potential (compared to control collagen), the
inhibitory effect of RGD and DGEA on osteoblastic
attachment was completely abolished.
In general these results are in agreement with our
hypothesis that AGEs-modification of type-I collagen,
interferes with the adhesion of osteoblasts to this ECM
protein mediated by the a and b subunits of integrin
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Fig. 4. Effect of co-incubation with 5mM DGEA on the morpho-
logical features of adhering UMR106 osteoblastic cells. Note the
difference with control in Fig. 3B. Objective: 40×.
receptors. In this context, it is significant to note that
the proportion of cell attachment to control collagen
which can be attributed to integrin/ECM interaction
in our experiments (20–40%) (Fig. 1), is practically
coincident with the AGEs-induced decrease in os-
teoblast adhesion to glycated collagen observed in
this (Table 1) and previous studies (40%) (McCarthy,
Etcheverry, Bruzzone et al., 2001).
There are several mechanisms by which AGEs
structures could impede integrin-mediated UMR106
cell adhesion. In the first place, our present results indi-
cate that glycated type-I collagen (versus control col-
lagen) shows a four-fold increase in AGEs-associated
fluorescence, a 28% reduction in free lysine ε-amino
residues and a 22% reduction in free arginine guani-
dinium residues. These in vitro results are similar to
the in vivo results found by other authors. For in-
stance, Tomasek et al. demonstrated that in 30-month
old (ageing) nondiabetic rats, cortical bone collagen
AGEs-specific fluorescence was 2.03 times higher that
in young (3-month old) non-diabetic rats (Tomasek
et al., 1994). These investigators also found a 1.7-fold
further increase in bone collagen fluorescence, in rats
that had been rendered diabetic for 2 months by strep-
tozotocin treatment. Other studies with non-diabetic
human individuals have found an age-induced de-
crease in free lysine and arginine residues of articular
cartilage collagen, this decrease reaching 7–10% of
lysine/arginine residues over the entire human life
span (0–80 years) (Verzijl et al., 2000). Although there
are no reports in the literature indicating the levels of
AGEs in type-I collagen from bone of human indi-
viduals with long-standing Diabetes mellitus, it is not
inconceivable to suppose that such levels could lead
to an approximately 15–20% decrease in collagen free
lysine and arginine residues (that is, approximately
double that of ageing non-diabetic humans). Interest-
ingly, it has been estimated that a 2-week incubation
of collagen with 0.1 M ribose is equivalent to the
exposure of this protein to physiological glucose con-
centrations for 20 years (Tanaka, Avigad, Eikenberry,
& Brodsky, 1988). Thus, our in vitro glycated type-I
collagen film could be an adequate model to represent
the AGEs-modified bone collagen of individuals with
long-standing Diabetes mellitus.
Arginine is included in the RGD tripeptide con-
sensus sequence for a1,5b1 integrins, and so its irre-
versible modification by a voluminous AGEs moiety
would be expected to directly interfere with a1,5b1
integrin-mediated osteoblastic adhesion. In fact, our
present results are very similar to reports by other
authors (Sakata et al., 2000), who have found a de-
crease in the attachment of vascular smooth muscle
cells to AGEs-modified fibronectin and type-I col-
lagen (versus control proteins). These authors also
noted that AGEs-modification of these ECM proteins
decreased their content of free arginine residues, and
abolished the inhibitory effect of externally added
RGD on vascular smooth muscle cell adhesion to the
matrix.
AGEs have also been shown to modify the struc-
ture and bioactivity of the proteins on which they are
formed due to their intrinsic volume and chemical
reactivity, and because they can form intra- and inter-
molecular crosslinks (Vlassara et al., 1994; Vlassara,
1997; McCarthy, Cortizo, Giménez Segura, Bruzzone,
& Etcheverry, 1998; Baynes & Thorpe, 1999;
McCarthy, 2000). Thus, the accumulation of AGEs on
a type-I collagen matrix can induce important confor-
mational changes in its structure, which would impair
its ability to interact efficiently with cellular receptors
such as integrins. In fact, this is probably the mecha-
nism which most adequately accounts for the relative
or absolute inability of DGEA or b-peptide to inhibit
osteoblastic adhesion to a glycated collagen matrix.
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In the present study, we also evaluated the possible
effect of DGEA, RGD or b-peptide on osteoblastic
spreading. Although in our experimental conditions
RGD did not induce changes in cellular spreading,
we found that in the presence of b-peptide UMR106
cells showed an increase in cell clumping and a de-
crease in cellular spreading, when plated both on gly-
cated and non-glycated collagen matrices (Fig. 3). In
the presence of DGEA, UMR106 osteoblasts plated
on non-glycated collagen (but not on AGEs-modified
collagen) showed an increase in spreading, with cel-
lular extensions in multiple directions (Fig. 4). All in
all, these morphological features are in general agree-
ment with the results of adhesion experiments, and
suggest that osteoblastic cells might be particularly
susceptible to alterations in cell–cell and cell–matrix
interactions when in the presence of molecules which
compete with integrin binding to ECM proteins. One
of the authors of the present work (T. Uemura) has
previously examined the effects of b-peptide on os-
teoblasts, fibroblasts and hepatoma cells cultured on
different ECM proteins (Yabe, Nemoto, & Uemura,
1997; Uemura et al., 1997; Liu et al., 1997; Sun et al.,
2000; Uemura et al., 2000). All the data from these
past experiments have clearly shown a dose-dependent
inhibitory effect of b-peptide on cell adhesion, via
interference with integrin recognition of ECM pro-
tein consensus sequences. Additionally, in the experi-
ments with osteoblasts and hepatoma cells, b-peptide
induced a decrease in cellular spreading and an in-
crease in cellular aggregation similar to that which we
have described in the present study. In particular, this
cellular aggregation (clumping) could be due either
to an enhancement of cell–cell interaction induced di-
rectly by b-peptide, or more probably to an increase
in cellular self-aggregation secondary to their detach-
ment from the matrix by b-peptide.
In conclusion, our present experiments confirm
the result of previous studies (McCarthy, Etcheverry,
Bruzzone et al., 2001) showing that glycation of a
type-I collagen matrix decreases its capacity for the
adhesion of UMR106 osteoblast-like cells. In addition,
we have provided evidence which strongly suggests
that this decreased attachment is the consequence of
an impaired interaction between osteoblastic a1,5b1
and a2b1 integrin receptors and AGEs-modified
type-I collagen, due to a direct or indirect structural
modification of the consensus sequences for these
integrins. If these results were to be extrapolated to
a clinical setting, AGEs-enriched bone ECM proteins
would possess a decreased potential for osteoblastic
attachment (and recruitment), and could thus con-
tribute to the development of diabetic osteopenia.
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